ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08905
-0,05%
Bitcoin
66.930,72
-0,22%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Vereinigtes Königreich
  5. LSE
  6. Camurus Ab (0RD1)

  7. Camurus Ab (0RD1) News

0RD1

Camurus Ab (0RD1)

Camurus Ab
Von:
Sortieren nach:
 Showing the most relevant articles for your search:LSE:0RD1
DatumZeitQuelleÜberschriftSymbolFirma
17/07/202307h40PR Newswire (US)Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegalyLSE:0RD1Camurus Ab
17/07/202307h36PR Newswire (US)Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegalyLSE:0RD1Camurus Ab
24/05/202305h25PR Newswire (US)Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorderLSE:0RD1Camurus Ab
24/05/202305h17PR Newswire (US)Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorderLSE:0RD1Camurus Ab
15/12/202123h15PR Newswire (US)Braeburn receives new Complete Response Letter for Brixadi in the USLSE:0RD1Camurus Ab
16/09/202111h38PR Newswire (US)FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver diseaseLSE:0RD1Camurus Ab
16/09/202111h37PR Newswire (US)FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver diseaseLSE:0RD1Camurus Ab
26/06/202118h09PR Newswire (US)Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the USLSE:0RD1Camurus Ab
26/06/202118h02PR Newswire (US)Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the USLSE:0RD1Camurus Ab
16/06/202100h12PR Newswire (US)Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the USLSE:0RD1Camurus Ab
16/06/202100h05PR Newswire (US)Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the USLSE:0RD1Camurus Ab
10/05/202117h22PR Newswire (US)Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injecti...LSE:0RD1Camurus Ab
10/05/202117h21PR Newswire (US)Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injecti...LSE:0RD1Camurus Ab
03/05/202108h42PR Newswire (US)The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependenceLSE:0RD1Camurus Ab
03/05/202108h40PR Newswire (US)The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependenceLSE:0RD1Camurus Ab
26/03/202114h33PR Newswire (US)Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependenceLSE:0RD1Camurus Ab
26/03/202114h32PR Newswire (US)Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependenceLSE:0RD1Camurus Ab
18/12/202008h27PR Newswire (US)Swissmedic approves Buvidal for the treatment of opioid dependenceLSE:0RD1Camurus Ab
18/12/202008h26PR Newswire (US)Swissmedic approves Buvidal for the treatment of opioid dependenceLSE:0RD1Camurus Ab
24/06/202014h38PR Newswire (US)Positive Results From Phase 2 Study of Once-weekly FluidCrystal® Formulation of Setmelanotide in Healthy Volunteers With Obe...LSE:0RD1Camurus Ab
23/06/202016h39PR Newswire (US)Camurus Raises Full Year 2020 Revenue GuidanceLSE:0RD1Camurus Ab
23/06/202016h33PR Newswire (US)Camurus Raises Full Year 2020 Revenue GuidanceLSE:0RD1Camurus Ab
01/06/202023h55PR Newswire (US)Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the USLSE:0RD1Camurus Ab
01/06/202023h52PR Newswire (US)Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the USLSE:0RD1Camurus Ab
14/05/202017h24PR Newswire (US)Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid DependenceLSE:0RD1Camurus Ab
14/05/202017h22PR Newswire (US)Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid DependenceLSE:0RD1Camurus Ab
07/05/202013h18PR Newswire (US)Camurus' Interim Report January-March 2020LSE:0RD1Camurus Ab
07/05/202013h17PR Newswire (US)Camurus' Interim Report January-March 2020LSE:0RD1Camurus Ab
02/04/202008h37PR Newswire (US)Camurus Announces Strong First Quarter Demand for Buvidal®LSE:0RD1Camurus Ab
02/04/202008h32PR Newswire (US)Camurus Announces Strong First Quarter Demand for Buvidal®LSE:0RD1Camurus Ab
 Showing the most relevant articles for your search:LSE:0RD1

Kürzlich von Ihnen besucht

TSXV
EEL
Esrey Energy Ltd.
BIT
UV8CPM
UniCredit Bank
BIT
F09578
Vontobel Financial Produ...
BIT
F16951
Vontobel Financial Produ...
USOTC
CVVRF
Vertical Exploration (PK)
BITMOT
889197
Bund Tf 0% Nv28 Eur
TSXV
MTX
Metalex Ventures
AMEX
SCZ
LSE
37YH
Qnb Fin 26
BIBX
KBCBTC
KaratBank Coin
EU
NLHCG
AEX Health Care Gross Re...
USOTC
PGPEF
Publicis Groupe Act (QX)
BOV
A1MT34M
Applied Materials
TSX
5893
Ravipa
EU
J843S
J843S
NYSE
EHD
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten